Skip to content
Triangle logo TriangleGet started
← Study library

NCT01259856 · CITED IN SOURCE DOCUMENTS

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2019-04-30

This research is looking at two conditions, Essential Thrombocythemia (ET) and Polycythemia Vera (PV). ET causes people to produce too many blood cells called platelets and PV causes too many platelets and red blood cells to be made. Platelets are particles which circulate in the blood stream and normally prevent bleeding and bruising. Having too many platelets in the blood increases the risk of developing blood clots, which can result in life threatening events like heart attacks and strokes. When the number of red blood cells is increased in PV this will slow the speed of blood flow in the body and increases the risk of developing blood clots. The purpose of this study is to look at the effectiveness of giving participants who have been diagnosed with ET or PV one of two different study regimens over time. The study subject will be followed for their condition for about 5 years. The subject will be randomized into one of two study regimens, either Pegylated Interferon Alfa-2a (PEGASYS) or Aspirin and Hydroxyurea (also called Hydroxycarbamide). The subject must be newly diagnosed or already receiving treatment for either PV or ET. Each of the study drugs used in this study is already being used to treat subjects with ET or PV currently, but the investigators are unsure which study drug is better.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Complete Remission (CR)

→

outcome · POSTED

Number of Participants With Partial Remission (PR)

→

outcome · POSTED

Number of Participants With Grade 3 and Grade 4 Hematological and Non-hematological Events

→

outcome · POSTED

Change in the Total Symptom Score (TSS)

→

outcome · POSTED

JAK2 Allele Burden

→

outcome · POSTED

Allele Burden

→

outcome · POSTED

Number of Participants With Progression of Disease or Death

→

outcome · POSTED

Number of Participants With Major Cardiovascular Events After Therapy

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * A diagnosis of Essential Thrombocythemia (ET) or Polycythemia Vera (PV) shall be made in accordance with the WHO (2008)criteria (Swerdlow 2008) as shown below. * Diagnosis \< 5 years prior to entry. * Polycythemia Vera (2 major criteria required) 1. Hb \>18.5g/dl (♂) or 16.5g/dl (♀) or HCT \>99 percentile reference range or Elevated red cell mass (\>25% above mean predicted value) or Hb \>17g/dl (♂) or 15g/dl (♀) if associated with a sustained rise from baseline with no apparent cause (e.g. treated iron deficiency). 2. Presence of JAK2V617F * If source documentation of diagnostic criterion #1 cannot be obtained, then diagnosis can be made with (1) the addition of an erythropoietin level below the reference range of normal AND (2) bone marrow biopsy showing hypercellularity for age with trilineage (panmyelosis) with prominent erythroid, granulocytic, and megakaryocytic proliferation. * Essential Thrombocythemia (all 6 criteria required) 1. Platelets count ≥ 450 x 10 to 9/L 2. Megakaryocyte proliferation with large and mature morphology. No significant increase or left shift of neutrophil granulopoiesis or erythropoiesis. Patients may have up to and including 2+ marrow reticulin fibrosis (0, 1 or 2 on scale 0 -4). 3. Not meeting WHO criteria for CML, PV, MDS, PMF or other myeloid neoplasm 4. Demonstration of clonal cytogenetic marker or no evidence of reactive thrombocytosis. 5. Absence of a leukoerythroblastic blood picture. 6. May participate in study without presence of JAK2V617F. Patients must have high risk disease as defined below: High risk PV ANY ONE of the following: * Age ≥ 60 years * Previous documented thrombosis, erythromelalgia or migraine (severe, recurrent, requiring medications, and felt to be secondary to the MPN) either after diagnosis or within 10 years before diagnosis and considered to be disease related * Significant splenomegaly (\> 5cm below the left costal margin on palpitation) or symptomatic splenomegaly (splenic infarcts or requiring analgesia) * Platelets ≥ 1000 x 10 to 9/L * Diabetes or hypertension requiring pharmacological therapy for \> 6 months High risk ET ANY ONE of the following: * Age ≥ 60 years * Platelet count ≥ 1500 x 10 to 9/L * Previous documented thrombosis, erythromelalgia or migraine headaches (severe, recurrent, requiring medications, and felt to be secondary to the MPN) either after diagnosis or within 10 years before diagnosis and considered to be disease related * Previous hemorrhage related to ET * Diabetes or hypertension requiring pharmacological therapy for \> 6 months Other Inclusion criteria (Both Strata) * Diagnosed less than 5 years prior to entry on trial * Never treated with cytoreductive drugs except hydroxyurea for up to 3 months maximum (phlebotomy, aspirin allowed, anagrelide allowed) * Age: ≥ 18 years (no upper limit) * Ability and willingness to comply with all study requirements * Signed informed consent to participate in this study. * Willing to participate in associated correlative science biomarker study * Serum creatinine ≤ 1.5 x upper limit of normal * ST and ALT ≤ 2 x upper limit of normal * No known PNH (paroxysmal nocturnal hemoglobinuria) clone * No concurrent hormonal oral contraceptive use Exclusion Criteria: (ANY of the following, both strata) * Known to meet the criteria for primary myelofibrosis (as opposed to ET) by WHO 2008 * Patients with a prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix) * Any contraindications to pegylated interferon or hydroxyurea * Presence of any life-threatening co-morbidity * History of active substance or alcohol abuse within the last year * Subjects who are pregnant, lactating or of reproductive potential and not practicing an effective means of contraception * History of psychiatric disorder (e.g. depression) Subjects with a history of mild depression may be considered for entry into this study, provided that a pretreatment assessment of the subject's affective status supports that the subject is clinically stable based on the investigator's normal practice for such subject. * History of autoimmune disorder (e.g. hepatitis) * Hypersensitivity to interferon alfa * Hepatitis B or C infection (HBV), or untreated systemic infection * Known HIV disease * Evidence of severe retinopathy (e.g. CMV retinitis, macular degeneration) or clinically relevant ophthalmological disorder (e.g. due to diabetes mellitus or hypertension) * History or other evidence of decompensated liver disease * History or other evidence of chronic pulmonary disease associated with functional limitation * Thyroid dysfunction not adequately controlled * Neutrophil count \<1.5 x 10 to 9/L * JAK2 exon 12 mutation: PV that lacks the JAK2V617F mutation but is characterized by the exon 12 mutation. * Meets criteria for post PV or post ET-MF * Subjects with any other medical condition, which in the opinion of the investigator would compromise the results of the study by deleterious effects of treatment. * Previous exposure to any formulation of pegylated interferon * History of major organ transplantation * History of uncontrolled severe seizure disorder * Inability to give informed written consent * Total bilirubin \>1.5 x ULN (patients that have an isolated indirect bilirubin that causes total bilirubin to be elevated beyond 1.5 x ULN due to documented Gilbert's syndrome or hemolysis may be included). No detectable PNH (paroxysmal nocturnal hemoglobinuria) clone where tested
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
    intervention Names
    1. Drug: PEGASYS
    2. Drug: Aspirin
    label
    PEGASYS
    type
    EXPERIMENTAL
  2. description
    Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
    intervention Names
    1. Drug: Hydroxyurea
    2. Drug: Aspirin
    label
    Hydroxyurea
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. PEGASYS
    description
    The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
    name
    PEGASYS
    other Names
    1. Pegylated Interferon Alfa-2a
    type
    DRUG
  2. arm Group Labels
    1. Hydroxyurea
    description
    Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
    name
    Hydroxyurea
    other Names
    1. Hydroxycarbamide
    type
    DRUG
  3. arm Group Labels
    1. Hydroxyurea
    2. PEGASYS
    description
    Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
    name
    Aspirin
    other Names
    1. acetylsalicylic acid
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
168
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Number of participants with Complete Remission after 12 months of therapy assessed by hematologic response rates two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET). Complete remission means no evidence of disease.
    measure
    Number of Participants With Complete Remission (CR)
    time Frame
    12 months
  2. description
    Number of participants with Partial Remission after 12 months of therapy assessed by hematologic response rates two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET). Partial Remission means decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    measure
    Number of Participants With Partial Remission (PR)
    time Frame
    12 months
secondary Outcomes
  1. description
    Number of Participants with Grade 3 and Grade 4 Hematological and Non-hematological Events using the Common Terminology Criteria for Adverse Events (CTCAE) 4.0 to assess the toxicity, safety and tolerability of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea).
    measure
    Number of Participants With Grade 3 and Grade 4 Hematological and Non-hematological Events
    time Frame
    4 years
  2. description
    Change in the Total Symptom Score which assessed improvement in disease symptoms measured by the change in TSS from the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) instrument being used in this study from baseline to 12 months. This 19 item instrument includes the previously validated 9 item brief fatigue inventory (BFI), symptoms related to splenomegaly, inactivity, cough, night sweats, pruritus, bone pains, fevers, weight loss, and an overall quality of life assessment. Each item is scored from 0-10 with full scale from 0-190, with higher scores mean worse symptoms.
    measure
    Change in the Total Symptom Score (TSS)
    time Frame
    baseline and 12 months
  3. description
    To compare the impact of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) on key biomarkers of the disease(s) by measuring the JAK2 allele burden.
    measure
    JAK2 Allele Burden
    time Frame
    4 years
  4. description
    The impact of PEGASYS on JAK2 will be measured by the allele burden; hematopoietic cell clonality will be measured by whether patients with clonal disease return to polyclonal; bone marrow histopathology will be measured by going from abnormal to normal; cytogenetic abnormalities will be measured by seeing if the cytogenetics go from abnormal to normal.To compare the impact of therapy on JAK2-V617F (JAK2), CALR, hematopoietic cell clonality in platelets and granulocytes in females, bone marrow histopathology, and cytogenetic abnormalities.
    measure
    Allele Burden
    time Frame
    4 years
  5. description
    Survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy To estimate survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) by capturing the rate of progression to a more advanced myeloid malignancy.
    measure
    Number of Participants With Progression of Disease or Death
    time Frame
    4 years
  6. measure
    Number of Participants With Major Cardiovascular Events After Therapy
    time Frame
    4 years
Full study description
brief Summary
This research is looking at two conditions, Essential Thrombocythemia (ET) and Polycythemia Vera (PV). ET causes people to produce too many blood cells called platelets and PV causes too many platelets and red blood cells to be made. Platelets are particles which circulate in the blood stream and normally prevent bleeding and bruising. Having too many platelets in the blood increases the risk of developing blood clots, which can result in life threatening events like heart attacks and strokes. When the number of red blood cells is increased in PV this will slow the speed of blood flow in the body and increases the risk of developing blood clots. The purpose of this study is to look at the effectiveness of giving participants who have been diagnosed with ET or PV one of two different study regimens over time. The study subject will be followed for their condition for about 5 years. The subject will be randomized into one of two study regimens, either Pegylated Interferon Alfa-2a (PEGASYS) or Aspirin and Hydroxyurea (also called Hydroxycarbamide). The subject must be newly diagnosed or already receiving treatment for either PV or ET. Each of the study drugs used in this study is already being used to treat subjects with ET or PV currently, but the investigators are unsure which study drug is better.
detailed Description
The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) are a group of clonal hematological malignancies that are characterized by a chronic course which can be punctuated by a number of disease related events including thrombosis, hemorrhage, pruritis and leukemic transformation. These disorders include Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PM). Recently an acquired somatic mutation in the intracellular kinase, JAK2 (JAK2V617F) has been observed in 95% of patients with PV, 50% of patients with ET and 50% of patients with primary myelofibrosis. At present the chemotherapeutic agent hydroxyurea is the standard of care for high risk patients with PV. Concern exists about prolonged use of this drug leading to leukemia and the inability of hydroxyurea to eliminate the malignant clone. Interferon (rIFN -2b), is a drug that appears to be non-leukemogenic, and may have a preferential activity on the malignant clone in PV, as suggested by cytogenetic remissions obtained in patients treated with rIFN -2b. Several investigators recently reported that patients with PV treated with rIFN -2b had lower JAK2V617F allele burdens as compared to a control group that included patients treated with phlebotomy, hydroxyurea, or anagrelide, or who remained untreated. The results confirm the hypothesis that rIFN -2b preferentially targets the malignant clone in PV and raises the possibility that the JAK2V617F allele burden, and a reversion of clonal hematopoiesis monitored in females by expression of X-chromosome polymorphic alleles maybe useful in monitoring minimal residual disease in PV patients. Pegylated Interferon Alfa-2a (PEGASYS) has been demonstrated in phase II trials of patients with PV and ET to have clinical efficacy as measured by normalization of myeloproliferation, lack of vascular events while on therapy, and a decrease in the JAK2V617F allele burden. Overall the tolerability of the therapy was good, with each of these trials having a dropout rate secondary to toxicity of less than 10% of those enrolled. Although dropout rates for toxicity were low, that is not to say the therapy was without symptomatic toxicity, and indeed a spectrum of toxicities might be encountered and need to be weighed in the analysis of the net clinical benefit patients experience on a clinical trial with Pegylated Interferon Alfa-2a. A new MPN assessment form will be utilized in this study. This 19 item instrument includes a previously validated 9 item brief fatigue inventory (BFI), symptoms related to splenomegaly, inactivity, cough, night sweats, pruritus, bone pains, fevers, weight loss, and an overall quality of life assessment. The instrument yields an independent result for each symptom (fatigue is a composite score), as this methodology (of linear analog scale assessment \[LASA\]) has proven very valid in the past. This instrument was validated prospectively (by comparison to a panel of instruments each containing an aspect of the MPN-SAF) for administration at a single time point. This is a randomized trial between hydroxyurea and Pegylated Interferon Alfa-2a, it is an open label clinical trial in two independent disease strata: (1) high risk polycythemia vera and (2) high risk essential thrombocythemia.
Source references
references
  1. citation
    Thanarajasingam G, Bhatnagar V, Noble BN, Chen TY, Fiero MH, Hoffman R, Jeffery M, Mazza GL, Mascarenhas J, Mesa R, Murugappan M, Ross J, Sidana S, Warsame R, Kluetz PG, Dueck AC. Longitudinal graphics of patient-reported physical function in patients treated for hematologic malignancies. BMC Med Res Methodol. 2025 Aug 7;25(1):189. doi: 10.1186/s12874-025-02617-y.
    pmid
    40775758
    type
    DERIVED
  2. citation
    Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing J, O'Connell CL, Kiladjian JJ, Mead AJ, Winton EF, Leibowitz DS, De Stefano V, Arcasoy MO, Kessler CM, Catchatourian R, Rondelli D, Silver RT, Bacigalupo A, Nagler A, Kremyanskaya M, Levine MF, Arango Ossa JE, McGovern E, Sandy L, Salama ME, Najfeld V, Tripodi J, Farnoud N, Penson AV, Weinberg RS, Price L, Goldberg JD, Barbui T, Marchioli R, Tognoni G, Rampal RK, Mesa RA, Dueck AC, Hoffman R. A randomized phase 3 trial of interferon-alpha vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022 May 12;139(19):2931-2941. doi: 10.1182/blood.2021012743.
    pmid
    35007321
    type
    DERIVED
  3. citation
    Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428.
    pmid
    31515250
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-1f8845ca749c605909fb
      requested nct id
      NCT01259856
      primary nct id
      NCT01259856
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      5d67acd07af1c8c398ca5fc68cf908fbd85fe3fe5708f4d51270231c1dd2f93e
      payload sha256
      393f4b903194e373f82d19a6485f2c19f118f82f059d8badfb4c90f8639db972
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-1f8845ca749c605909fb
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT01259856
      occurrences
      1. context exact
        HealthProfessional&amp;language=English'); return(false);">Level of evidence C3</a>] </li></ul></div></li><li>The randomized phase III <a href="/clinicaltrials/NCT01259856">MPN-RC 112</a> study (NCT01259856) included 87 patients with high-risk PV. Patients were randomly assigned to receive either hydroxyurea or pegylated interfer
        end
        31897
        exact text
        NCT01259856
        start
        31886
      2. context exact
        lish'); return(false);">Level of evidence C3</a>] </li></ul></div></li><li>The randomized phase III <a href="/clinicaltrials/NCT01259856">MPN-RC 112</a> study (NCT01259856) included 87 patients with high-risk PV. Patients were randomly assigned to receive either hydroxyurea or pegylated interferon alfa.[<a href="#cit/section_3.20
        end
        31932
        exact text
        NCT01259856
        start
        31921
      3. context exact
        reduction in thrombosis for patients older than 60 years.[<a href="#cit/section_4.32">32</a>] In a phase II study (<a href="https://clinicaltrials.gov/ct2/show/NCT01259856" title="https://clinicaltrials.gov/ct2/show/NCT01259856">NCT01259856</a>), 65 patients with ET who required therapy with hydroxyurea and had either an inadequa
        end
        63727
        exact text
        NCT01259856
        start
        63716
      4. context exact
        .[<a href="#cit/section_4.32">32</a>] In a phase II study (<a href="https://clinicaltrials.gov/ct2/show/NCT01259856" title="https://clinicaltrials.gov/ct2/show/NCT01259856">NCT01259856</a>), 65 patients with ET who required therapy with hydroxyurea and had either an inadequate response or unacceptable side effects received pegyla
        end
        63783
        exact text
        NCT01259856
        start
        63772
      5. context exact
        it/section_4.32">32</a>] In a phase II study (<a href="https://clinicaltrials.gov/ct2/show/NCT01259856" title="https://clinicaltrials.gov/ct2/show/NCT01259856">NCT01259856</a>), 65 patients with ET who required therapy with hydroxyurea and had either an inadequate response or unacceptable side effects received pegylated interfero
        end
        63796
        exact text
        NCT01259856
        start
        63785
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/386d32d532a5041e68.html
      source file sha256
      5d67acd07af1c8c398ca5fc68cf908fbd85fe3fe5708f4d51270231c1dd2f93e
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:22:08.366806+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      04fd1210e35e69a6987a4d0936de42da25c4659d300c8be83cd5fb6547471174
      source title
      Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: September 27, 2024
        datetime
        2024-09-27T12:00:00Z
        display
        September 27, 2024

    Preserved source evidence · Not medical advice